NYSE:SYK
STRYKER CORP
A premier medical technology leader delivering advanced orthopaedic, trauma, and neurotechnology solutions to global healthcare providers.
Key Metrics
Investment Thesis
Bull Case
Stryker offers a compelling long-term value proposition backed by consistent revenue growth from $18.45B in 2022 to $25.12B in 2025 and improving net margins reflected in rising profits. The company's strong balance sheet with $4.01B in cash and equivalents provides ample runway for R&D investments and shareholder returns via dividends totaling $1.28B. Strategic acquisitions enhance its product portfolio while organic growth in robotics and neurotechnology segments diversifies revenue streams beyond traditional implants.
Bear Case
Valuation concerns persist given the massive goodwill of $19.29B, which could be impaired if acquisition synergies fail to materialize as expected. The significant cash outflow from investing activities and other financing flows suggests the company is burning capital faster than it can sustainably reinvest without dilution or debt. Regulatory uncertainty regarding Medicare reimbursement rates poses a systemic risk that could compress margins across all orthopedic segments regardless of operational execution.
About STRYKER CORP
Stryker Corporation is a leading global medical technology company specializing in orthopaedics, neurotechnology, and trauma care solutions. The company serves hospitals, ambulatory surgery centers, and healthcare providers worldwide with innovative surgical systems, implants, and robotics. With revenue growth driven by strategic acquisitions and organic innovation in high-growth orthopedic sub-sectors, Stryker maintains a dominant market position.
Analysis
Management Discussion
Stryker delivered robust financial performance in 2025, generating $3.25B in net profit and growing revenue to $25.12B from the prior year's $22.59B. The company successfully navigated macroeconomic pressures while maintaining strong operational efficiency, evidenced by operating cash flows of $5.04B significantly exceeding net income. However, significant capital outflows of $4.87B from investing activities and other financing outflows of $5.55B indicate heavy investment in acquisitions that may temporarily suppress near-term liquidity.
Industry Overview
The global medical device industry is undergoing rapid transformation driven by aging demographics, technological advancements in robotics, and a shift toward value-based care models. Companies like Stryker compete against giants like Medtronic and DePuy Synthes to capture market share in high-value orthopedic procedures while navigating strict FDA regulations. Industry consolidation continues as larger players seek to acquire niche innovators to expand their technological footprints and geographic reach.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $18.45B | $20.50B | $22.59B | $25.12B |
| Cost of Revenue | $6.87B | $7.44B | $8.15B | $9.05B |
| Gross Profit | $11.58B | $13.06B | $14.44B | $16.07B |
| Operating Expenses | $8.74B | $9.17B | $10.75B | $11.18B |
| Operating Income | $2.84B | $3.89B | $3.69B | $4.89B |
| R&D | $1.45B | $1.39B | $1.47B | $1.62B |
| G&A | $6.46B | $7.13B | $7.68B | $8.65B |
| Stock-Based Comp | $168.0M | $205.0M | $229.0M | $243.0M |
| D&A | $1.28B | $1.34B | $1.43B | $1.57B |
| Depreciation | $371.0M | $393.0M | $427.0M | $461.0M |
| Amortization | $627.0M | $635.0M | $623.0M | $732.0M |
| Other OpEx | $828.0M | $653.0M | $1.60B | $902.0M |
| Non-Operating Income | $-158.0M | $-215.0M | $-197.0M | $-375.0M |
| Pre-Tax Income | $2.68B | $3.67B | $3.49B | $4.51B |
| Income Tax | $325.0M | $508.0M | $499.0M | $1.27B |
| Continuing Ops | $2.36B | $3.17B | $2.99B | $3.25B |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $2.36B | $3.17B | $2.99B | $3.25B |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $2.36B | $3.17B | $2.99B | $3.25B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $10.28B | $12.52B | $14.85B | $14.76B |
| Cash & Equivalents | $1.84B | $2.97B | $3.65B | $4.01B |
| Accounts Receivable | $3.56B | $3.77B | $3.99B | $4.04B |
| Inventory | $4.00B | $4.84B | $4.77B | $5.31B |
| Other Current Assets | $871.0M | $939.0M | $2.43B | $1.40B |
| Long-Term Assets | $26.61B | $27.39B | $28.12B | $33.09B |
| PP&E (Net) | $2.97B | $3.21B | $3.45B | $3.88B |
| Intangibles | $4.88B | $4.59B | $4.39B | $5.68B |
| Goodwill | $14.88B | $15.24B | $15.86B | $19.29B |
| Operating Leases | $473.0M | $494.0M | $516.0M | $519.0M |
| Other LT Assets | $3.40B | $3.85B | $3.91B | $3.72B |
| Total Assets | $36.88B | $39.91B | $42.97B | $47.84B |
| Current Liabilities | $6.30B | $7.92B | $7.62B | $7.79B |
| Current Leases | $121.0M | $143.0M | $144.0M | $153.0M |
| Taxes Payable | $292.0M | $391.0M | $539.0M | $418.0M |
| Other Current Liab | $5.61B | $7.08B | $6.61B | $6.89B |
| Long-Term Liabilities | $13.96B | $13.40B | $14.72B | $17.63B |
| Long-Term Debt | $11.86B | $10.90B | $12.19B | $14.86B |
| LT Operating Leases | $357.0M | $356.0M | $379.0M | $348.0M |
| Other LT Liab | $1.11B | $1.57B | $1.80B | $2.02B |
| Total Liabilities | $20.27B | $21.32B | $22.34B | $25.42B |
| Shareholders' Equity | $16.62B | $18.59B | $20.63B | $22.42B |
| Retained Earnings | $14.77B | $16.77B | $18.53B | $20.47B |
| AOCI | $-221.0M | $-416.0M | $-293.0M | $-687.0M |
| Total L&E | $36.88B | $39.91B | $42.97B | $47.84B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $2.36B | $3.17B | $2.99B | $3.25B |
| Non-Cash Adjustments | $-1.56B | $-1.17B | $266.0M | $891.0M |
| Working Capital Changes | $1.83B | $1.71B | $983.0M | $907.0M |
| Cash from Operations | $2.62B | $3.71B | $4.24B | $5.04B |
| Capital Expenditures | $588.0M | $575.0M | $755.0M | $761.0M |
| Cash from Investing | $-2.92B | $-962.0M | $-3.00B | $-4.87B |
| Debt Issuances | $1.50B | $1.24B | $3.01B | $2.98B |
| Debt Repayments | $653.0M | $2.06B | $2.04B | $1.40B |
| Dividends Paid | $1.05B | $1.14B | $1.22B | $1.28B |
| Cash from Financing | $-749.0M | $-1.59B | $-525.0M | $113.0M |
| FX Effect | $-51.0M | $-28.0M | $-36.0M | $68.0M |
| Net Change in Cash | $-1.10B | $1.13B | $681.0M | $359.0M |
| Beginning Cash | $2.94B | $1.84B | $2.97B | $3.65B |
| Ending Cash | $1.84B | $2.97B | $3.65B | $4.01B |
Frequently Asked Questions
How does STRYKER CORP make money?
The company's revenue is primarily segmented into Orthopaedics (serving hip and knee markets), Neurotechnology (spinal cord stimulation and surgical robotics), and Trauma (orthopedic implants for fractures). These segments reflect a diversified portfolio spanning high-volume consumables, complex implantable devices, and cutting-edge surgical robotics platforms.
What are the main risks for SYK?
Regulatory headwinds from CMS and international payers threatening reimbursement rates for advanced implants and robotics procedures. Intense competition from Medtronic, Johnson & Johnson, and emerging digital health startups eroding market share in consumable segments. Integration risks associated with large-scale acquisitions such as the recent $4.96B acquisition activity impacting short-term cash flow. Potential supply chain disruptions affecting inventory levels given current inventory holdings of $5.31B.
What is SYK's competitive advantage?
Stryker possesses deep technological moats through its proprietary surgical robotics platforms and extensive surgeon training ecosystems. Its massive cash reserves and consistent free cash flow generation provide significant flexibility for strategic M&A to acquire emerging technologies. The company benefits from strong pricing power in the orthopaedic space due to high switching costs associated with its integrated system offerings.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.